Skip to main content

Table 8 Relationships between rheumatoid arthritis clinical features and muscle metabolic intermediates

From: Molecular alterations in skeletal muscle in rheumatoid arthritis are related to disease activity, physical inactivity, and disability

  Disease activity Disability Pain Exercise (min/d) Physical activity (MET h/d)
Amino acids      
Glycine 0.33b 0.50a 0.23 0.11 0.02
Alanine -0.31b 0.03 -0.01 0.11 0.08
Serine 0.31b 0.20 0.17 -0.03 -0.01
Proline 0.20 0.36a 0.09 0.05 0.08
Valine 0.12 0.11 -0.04 0.05 -0.01
Leucine/isoleucine 0.09 0.18 -0.01 -0.08 -0.16
Methionine 0.07 0.16 -0.17 -0.01 -0.04
Histidine -0.08 -0.02 -0.12 0.23 0.19
Phenylalanine -0.06 -0.04 -0.21 0.06 0.04
Tyrosine -0.06 0.08 -0.13 0.13 0.14
Aspartate/asparagine 0.34b 0.36a 0.20 -0.13 -0.12
Glutamate/glutamine 0.20 0.24 0.06 -0.12 -0.04
Ornithine 0.32b 0.39a 0.14 -0.21 -0.20
Citrulline 0.08 0.21 0.13 -0.02 0.13
Arginine 0.27 0.45a 0.24 -0.26 -0.27
Organic acids      
Lactate -0.09 -0.18 -0.06 -0.09 -0.12
Pyruvate -0.22 -0.22 -0.21 0.16 0.05
Succinate 0.03 -0.01 0.15 -0.06 -0.12
Fumarate -0.34b -0.24 -0.15 0.05 -0.01
Malate -0.28 -0.14 0.04 -0.01 -0.07
alphaKetoglutarate -0.22 -0.03 -0.03 0.27 0.18
Citrate 0.17 0.23 0.29 0.05 0.14
Acylcarnitines      
Free carnitine: C0 -0.10 0.19 0.10 0.04 0.08
C2 -0.07 0.08 0.07 -0.22 -0.02
C3 -0.05 0.10 -0.01 0.10 0.00
C4/Ci4 -0.02 -0.13 -0.20 0.09 0.16
C5:1 0.15 0.09 0.06 -0.10 0.05
C5 0.01 0.05 -0.24 0.14 0.10
C4OH 0.11 0.09 0.11 -0.11 -0.04
C6 0.05 -0.10 -0.24 0.30 0.29
C5OH -0.24 0.04 0.14 0.14 0.25
C3DC -0.17 0.13 0.03 -0.02 0.10
C4DC/Ci4DC 0.02 0.28b 0.05 -0.32b -0.23
C8:1 -0.10 -0.05 -0.15 -0.07 0.00
C8 0.01 -0.11 -0.13 0.16 0.13
C5DC 0.19 0.20 0.03 -0.12 -0.11
C8:1OH/C6:1 DC 0.11 0.21 0.12 -0.05 -0.11
C6DC/C8OH -0.02 0.03 -0.10 0.08 0.11
C10:3 0.02 0.15 0.15 -0.10 -0.09
C10:2 0.00 0.06 -0.05 -0.14 -0.20
C10:1 -0.09 -0.09 -0.08 0.19 0.11
C10 -0.05 -0.12 -0.13 0.15 0.14
C7DC 0.04 0.13 0.06 -0.20 -0.20
C8:1 DC -0.17 -0.03 -0.13 -0.06 -0.09
C10OH:C8DC -0.08 0.00 -0.15 0.06 0.07
C12:2 0.04 -0.01 -0.08 -0.24 -0.26
C12:1 -0.14 -0.12 -0.13 0.14 0.12
C12 -0.20 -0.22 -0.19 0.20 0.19
C12:2OH/C10:2 DC -0.19 -0.03 -0.14 0.06 0.00
C12:1OH/C10:1 DC -0.19 -0.07 -0.16 0.15 0.18
C12OH/C10DC -0.16 0.03 -0.13 0.13 0.14
C14:3 -0.14 -0.09 -0.15 0.19 0.20
C14:2 -0.22 -0.17 -0.22 0.27 0.26
C14:1 -0.18 -0.16 -0.17 0.21 0.21
C14 -0.25 -0.21 -0.26 0.24 0.22
C14:3OH/C12:3 DC -0.05 0.08 -0.01 -0.03 0.12
C14:2OH/C12:2 DC -0.12 -0.03 -0.20 0.04 0.03
C14:1OH/C12:1 DC -0.24 -0.11 -0.19 0.14 0.17
C14OH/C12DC -0.13 0.03 -0.14 0.16 0.17
C16:3 -0.28 -0.19 -0.22 0.26 0.27
C16:2 -0.34b -0.26 -0.26 0.35a 0.33b
C16:1 -0.28 -0.22 -0.17 0.22 0.18
C16 -0.27 -0.20 -0.19 0.17 0.18
C16:3OH/C14:3-DC -0.16 -0.10 -0.03 0.11 0.19
C16:2OH/C14:2 DC -0.26 -0.16 -0.19 0.12 0.10
C16:1OH/C14:1 DC -0.25 -0.09 -0.21 0.10 0.12
C16OH/C14DC -0.17 0.04 -0.08 0.10 0.12
C18:3 -0.43a -0.36a -0.19 0.20 0.19
C18:2 -0.40a -0.39a -0.19 0.23 0.18
C18:1 -0.33b -0.32b -0.15 0.15 0.13
C18 -0.21 -0.13 -0.12 0.06 0.09
C18:3OH/C16:3 DC -0.29 -0.06 -0.02 0.18 0.18
C18:2OH/C16:2 DC -0.31b -0.06 -0.08 0.12 0.14
C18:1OH/C16:1 DC -0.22 0.02 -0.04 0.06 0.07
C18OH/C16DC -0.18 0.03 -0.08 -0.03 0.00
C20:4 -0.28 -0.30b -0.12 0.26 0.27
C20:3 -0.29b -0.37a -0.11 0.18 0.17
C20:2 -0.25 -0.20 -0.14 0.11 0.14
C20:1 -0.25 -0.16 -0.11 0.07 0.08
C20 -0.18 -0.04 -0.09 -0.02 -0.01
C20:3OH/C18:3 DC 0.09 0.21 -0.01 -0.14 -0.08
C20:2OH/C18:2 DC -0.16 -0.15 0.06 -0.14 -0.14
C20:1OH/C18:1 DC -0.03 0.18 -0.03 0.00 0.04
C20OHC18DC/C22:6 -0.16 0.00 -0.09 -0.05 -0.08
C22:5 -0.28 -0.20 -0.14 0.15 0.09
C22:4 -0.22 -0.24 -0.06 0.07 0.09
C22:3 -0.03 -0.11 0.01 -0.06 -0.03
C22:2 0.13 -0.01 -0.06 0.09 0.24
C22:1 0.06 0.01 -0.12 0.28 0.36
C22 -0.02 -0.06 0.00 0.03 0.10
  1. Data are shown as Spearman correlation coefficients. aSignificant relationships (p < 0.05) to all red and green color and bSignificant relationships r ≥ |0.35| to all bright red and green
Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us